IP Library Granted Patent US 9,914,688
Granted Patent B2
US 9,914,688 · App. 15/067,993 · Granted Mar 13, 2018

Optically pure benzyl-4-chlorophenyl-C-glucoside derivative

Inventor: Frank Wu (Jinan, CN)
Assignees: SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.; XUANZHU PHARMA CO., LTD.
C07C43/247A61K31/155A61K31/351A61K31/403A61K31/4985A61K31/7004A61K45/06C07D309/10C07C2602/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,914,688
App. No.
15/067,993
Granted
Mar 13, 2018
Kind
B2
Abstract

The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity)

Claims (8)

1. An intermediate for the compound represented by formula (II),

which is (2S,3R,4R,5S,6R)-2-(3-(4-(((1R,3s,5S)-bicyclo[3.1.0]hexan-3-yl)oxy)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol,

wherein said intermediate is

wherein X represents bromo or iodo.

2. An intermediate for the compound represented by formula (III),

(III), which is (2S,3R,4R,5S,6R)-2-(3-(4-(((1R,3r,5S)-bicyclo[3.1.0]hexan-3-yl)oxy)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol,

wherein said intermediate is

wherein X represents bromo or iodo.

Assignments (5)
CHANGE OF NAME Recorded Sep 15, 2023
From: JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD
To: HUISHENG BIOPHARMACEUTICAL CO., LTD.
Reel/Frame 064915/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2021
From: XUANZHU PHARMA CO., LTD.
To: JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD.; BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD.
Reel/Frame 056110/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2019
From: SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
To: XUANZHU PHARMA CO., LTD.
Reel/Frame 049930/0676 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2018
From: XUANZHU PHARMA CO., LTD.
To: SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Reel/Frame 044557/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2016
From: WU, FRANK
To: XUANZHU PHARMA CO., LTD.
Reel/Frame 037968/0176 →
Continuity (2)
Division 14146838 · Jan 3, 2014
Related Publication 20160194264A1 · Jul 7, 2016